# Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy

> **NCT05222971** · PHASE2 · RECRUITING · sponsor: **Asan Medical Center** · enrollment: 62 (estimated)

## Conditions studied

- Biliary Tract Cancer
- DNA Damage Repair Deficiency

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT05222971
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-01
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2025-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05222971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05222971, "Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05222971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*